Preparation and Aggregation of Aß1-42 Peptide

Compound MR-39 ((S)-3-(4-cyanophenyl)-N-[[1-(3-chloro-4-fluorophenyl)cyclopropyl]methyl]-2-[3-(4-fluorophenyl)ureido]propanamide) was prepared as described previously in Stama et al. (2017) [29 (link)]. The FPR2 antagonist WRW4 was purchased from Alomone Labs, Israel. Aβ_1-42 (Kaneka Eurogentec Inc, Belgium) was prepared according to the commonly accepted method described by Dahlgren et al. (2002) [30 (link)]. Briefly, Aβ_1-42 was dissolved in HFIP (hexafluoroisopropanol, Sigma-Aldrich, St. Louis, MO, USA). Next, HFIP was removed under vacuum, and the peptide film was stored at − 20 °C. For the aggregation studies, the peptide was initially resuspended in DMSO (Sigma-Aldrich, St. Louis, MO, USA). For oligomeric conditions, culture media was added, and the peptide was incubated at 4 °C for 24 h. For fibrillar conditions, 10 mM HCl was added, and the peptide was incubated for 24 h at 37 °C [30 (link), 31 (link)].